Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026)
Perrigo (PRGO) reported Non-Current Deferred Tax Liability of $153.5 million for Q1 2026, down 18.87% year-over-year from $189.2 million in Q1 2025, and down 9.12% quarter-over-quarter from $168.9 million in Q4 2025.
Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Non-Current Deferred Tax Liability data on file, last reported at $153.5 million in Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $153.5 million, down 18.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.5 million (down 18.87% YoY), and the FY2025 annual result was $168.9 million, down 65.5% from the prior year.
- Non-Current Deferred Tax Liability slipped to $153.5 million in Q1 2026 per PRGO's latest filing, from $168.9 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $489.6 million in Q4 2024 and troughed at $153.5 million in Q1 2026.
- A 5-year average of $280.8 million and a median of $247.7 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability jumped 86.66% in 2024, then slumped 65.5% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $368.2 million in 2022, then decreased by 28.76% to $262.3 million in 2023, then surged by 86.66% to $489.6 million in 2024, then tumbled by 65.5% to $168.9 million in 2025, then declined by 9.12% to $153.5 million in 2026.
- Business Quant data shows PRGO's Non-Current Deferred Tax Liability at $153.5 million in Q1 2026, $168.9 million in Q4 2025, and $194.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 153.50 Mn |
| Mar 28, 2026 | 153.50 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Dec 31, 2024 | 489.60 Mn |
| Dec 31, 2024 | 489.60 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Mar 30, 2024 | 247.70 Mn |
| Mar 30, 2024 | 247.70 Mn |
| Dec 31, 2023 | 262.30 Mn |
| Dec 31, 2023 | 262.30 Mn |